Philip Austin
Founding Partner @ Anterra Capital
Boston, United States
Philip Austin is a Series B investor at Anterra Capital in Boston focused on Biotechnology and Biopharma. Philip is a founding partner at Anterra Capital, a leading specialist investment fund in the food & agricultural sector. He currently heads up Anterra’s US office, dedicating most of his investment efforts to furthering life science companies in the food & agricultural sector. Prior to co-founding Anterra, Philip worked in the principalinvestment team of Rabobank International (Amsterdam, Netherlands), supporting this global leader in agricultural banking to make investments in groundbreaking, early stage technology companies. Philip started his investment career with Atlas Venture in London, United Kingdom. Prior to this, he was a strategy consultant with McKinsey & Company's London and Washington, D.C. offices. Philip holds a dual degree in Pharmaceutical Chemistry and Chemical Engineering.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Philip Austin invests in
Stages Philip Austin invests in
Countries Philip Austin invests in
Investment Focus
Industry
- Biotechnology 3 (50%)
- Biopharma 1 (17%)
- Veterinary 1 (17%)
- Health Care 1 (17%)
- Therapeutics 1 (17%)
Stage
- Series B 3 (50%)
- Series A 2 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Animol Discovery
|
Animol is building its own pipeline of break-through proprietary veterinary small molecules led by a team of animal health industry experts with vast experience in bringing drugs to market. With our unique and powerful technology platform we deliver innovative medicines that are specifically designed for the needs of veterinary patients. | $34M / Series B / Jul 28, 2022 | |
Invetx
|
Invetx is a veterinary therapeutics company that focuses on biopharmaceuticals that bring human biotechnology to animal health.Invetx is building the world’s premier animal health biotechnology innovation platform for protein-based therapeutics.Working closely with best-in-class biotechnology companies, major investors and an extensive networkof industry experts, Invetx is focused on guiding the development of an exciting portfolio of therapies and technologies to deliver the future of animal care.Invetx's network includes experts in both animal and human health, veterinary scientists and clinicians. The company's vision is of a global animal health industry that fully leverages biopharma technologies to deliver dramatically improved health outcomes for pets and farm animal populations. | $60.5M / Series B / May 10, 2022 | |
|
Invetx
|
Invetx is a veterinary therapeutics company that focuses on biopharmaceuticals that bring human biotechnology to animal health.Invetx is building the world’s premier animal health biotechnology innovation platform for protein-based therapeutics.Working closely with best-in-class biotechnology companies, major investors and an extensive networkof industry experts, Invetx is focused on guiding the development of an exciting portfolio of therapies and technologies to deliver the future of animal care.Invetx's network includes experts in both animal and human health, veterinary scientists and clinicians. The company's vision is of a global animal health industry that fully leverages biopharma technologies to deliver dramatically improved health outcomes for pets and farm animal populations. | $10.3M / Series A / Sep 30, 2020 | |
|
Invetx
|
Invetx is a veterinary therapeutics company that focuses on biopharmaceuticals that bring human biotechnology to animal health.Invetx is building the world’s premier animal health biotechnology innovation platform for protein-based therapeutics.Working closely with best-in-class biotechnology companies, major investors and an extensive networkof industry experts, Invetx is focused on guiding the development of an exciting portfolio of therapies and technologies to deliver the future of animal care.Invetx's network includes experts in both animal and human health, veterinary scientists and clinicians. The company's vision is of a global animal health industry that fully leverages biopharma technologies to deliver dramatically improved health outcomes for pets and farm animal populations. | $15M / Series A / Feb 24, 2020 | |
|
Animol Discovery
|
Animol is building its own pipeline of break-through proprietary veterinary small molecules led by a team of animal health industry experts with vast experience in bringing drugs to market. With our unique and powerful technology platform we deliver innovative medicines that are specifically designed for the needs of veterinary patients. | $6M / Series A / Jan 01, 2020 | |
Caribou Biosciences
|
Caribou Biosciences is a operator of a medical technology company intended to analyze cell and genome engineering. The company specializes in cellular engineering and analysis based on the CRISPR-Cas9 technology platform which paired with a guide RNA, cuts double-stranded DNA and allows for specific changes to DNA, enabling development oftherapeutics for agricultural biotechnology, industrial biotechnology and basic and applied biological research. | $30M / Series B / May 16, 2016 |
Co-Investors
AbCellera
2 deals together
Casdin Capital
2 deals together
F-Prime
2 deals together
Google Ventures
2 deals together
Tekla Capital Management
2 deals together
WuXi Biologics
2 deals together
About Anterra Capital
Anterra Capital is an independent growth capital fund. They invest in fast growing companies that are working to make the global food supply chain safer, more efficient and more sustainable. Their focus is on supporting the growth of companies who are commercializing novel technologies and services. They invest across the food supply chain fromnovel agro inputs and precision farming through to smarter logistics and consumer safety. They do not invest in other funds, land, operating assets, or other capital intensive businesses.They are a lead investor taking significant minority equity positions and performing an active role on the boards of the companies they support. At the time they invest, their companies typically already generate revenue and have great growth prospects. They target investments of EUR 1M to EUR 15M per company and often support their portfolio companies in raising additional capital from professional investors including from their own financial partners. Importantly, they are long-term investors. They focus on working closely with management teams to build lasting value.
Anterra Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Adam Anders
Managing Partner
|
|||
Brett Chevalier
Venture Partner
|
|||
Brett Wong
Principal
|
|||
Maarten Goossens
Principal
|
|||
|
Philip Austin
Founding Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Philip Austin invest in?
Philip Austin invests primarily in Biotechnology, Biopharma and Veterinary startups, most often at Series B and Series A stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Philip Austin last invest?
The most recent investment recorded for Philip Austin closed in Jul 2022. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
